Continuous cytomegalovirus seroconversion in a large group of healthy blood donors

被引:103
作者
Hecker, M [1 ]
Qiu, D [1 ]
Marquardt, K [1 ]
Bein, G [1 ]
Hackstein, H [1 ]
机构
[1] Univ Giessen, Inst Clin Immunol & Transfus Med, Dept Med Comp, D-35390 Giessen, Germany
关键词
CMV; epidemiology; infection; seroconversion;
D O I
10.1111/j.0042-9007.2004.00388.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives: Transmission of cytomegalovirus (CMV) to seronegative, immunocompromised recipients can cause serious and fatal complications. Although the seroprevalence of CMV is high, the risk of primary CMV infection among healthy blood donors has not yet been analysed in a large population. Materials and Methods: We developed an algorithm to determine the rate of CMV seroconversion in an overall cohort of 24 260 subjects who donated 176 474 blood units during an 11-year observation period. Results: We detected CMV seroconversion in all relevant age groups (18-60 years) with an overall seroconversion rate of 0.55% per year. Both CMV seroconversion and seroprevalence occurred more frequently in female donors (P = 0.02 and P < 0.001, respectively). We identified 30-35-year-old blood donors as the group with the highest rate of CMV seroconversion per year (1.33% vs. 0.46%; P < 0.0001). Conclusions: We conclude that the risk of primary CMV infection is a continuous life-long event and correlates with age and female gender.
引用
收藏
页码:41 / 44
页数:4
相关论文
共 23 条
[1]   FAILURE TO DETECT HUMAN CYTOMEGALOVIRUS DNA IN PERIPHERAL-BLOOD LEUKOCYTES OF HEALTHY BLOOD-DONORS BY THE POLYMERASE CHAIN-REACTION [J].
BITSCH, A ;
KIRCHNER, H ;
DUPKE, R ;
BEIN, G .
TRANSFUSION, 1992, 32 (07) :612-617
[2]   CYTOMEGALOVIRUS IMMUNE GLOBULIN AND SERONEGATIVE BLOOD PRODUCTS TO PREVENT PRIMARY CYTOMEGALOVIRUS-INFECTION AFTER MARROW TRANSPLANTATION [J].
BOWDEN, RA ;
SAYERS, M ;
FLOURNOY, N ;
NEWTON, B ;
BANAJI, M ;
THOMAS, ED ;
MEYERS, JD .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (16) :1006-1010
[3]   A COMPARISON OF FILTERED LEUKOCYTE-REDUCED AND CYTOMEGALOVIRUS (CMV) SERONEGATIVE BLOOD PRODUCTS FOR THE PREVENTION OF TRANSFUSION-ASSOCIATED CMV INFECTION AFTER MARROW TRANSPLANT [J].
BOWDEN, RA ;
SLICHTER, SJ ;
SAYERS, M ;
WEISDORF, D ;
CAYS, M ;
SCHOCH, G ;
BANAJI, M ;
HAAKE, R ;
WELK, K ;
FISHER, L ;
MCCULLOUGH, J ;
MILLER, W .
BLOOD, 1995, 86 (09) :3598-3603
[4]   Cytomegalovirus as a cause of very late interstitial pneumonia after bone marrow transplantation [J].
de Medeiros, CR ;
Moreira, VA ;
Pasquini, R .
BONE MARROW TRANSPLANTATION, 2000, 26 (04) :443-444
[5]   Frequency and duration of plasma CMV viremia in seroconverting blood donors and recipients [J].
Drew, WL ;
Tegtmeier, G ;
Alter, HJ ;
Laycock, ME ;
Miner, RC ;
Busch, MP .
TRANSFUSION, 2003, 43 (03) :309-313
[6]   OCCUPATIONAL RISK FOR PRIMARY CYTOMEGALOVIRUS-INFECTION AMONG PEDIATRIC HEALTH-CARE WORKERS [J].
DWORSKY, ME ;
WELCH, K ;
CASSADY, G ;
STAGNO, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (16) :950-953
[7]   CYTOMEGALOVIRUS STUDIES ON BLOOD-DONORS IN NORTH-EAST SCOTLAND AND A REVIEW OF UK DATA [J].
GALEA, G ;
URBANIAK, SJ .
VOX SANGUINIS, 1993, 64 (01) :24-30
[8]   THE RISK OF CYTOMEGALOVIRUS-INFECTION IN SOLID ORGAN AND BONE-MARROW TRANSPLANT RECIPIENTS - TRANSFUSION OF BLOOD PRODUCTS [J].
HILLYER, CD ;
SNYDMAN, DR ;
BERKMAN, EM .
TRANSFUSION, 1990, 30 (07) :659-666
[9]   Cytomegalovirus antibody status and renal transplantation: 1987-1994 [J].
Hirata, M ;
Terasaki, PI ;
Cho, YW .
TRANSPLANTATION, 1996, 62 (01) :34-37
[10]  
Laupacis Andreas, 2001, Transfusion (Bethesda), V41, P560, DOI 10.1046/j.1537-2995.2001.41040560.x